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Background: Evidence for opioid-induced hyperalgesia (OIH) has been shown in animal and 
human studies, but the clinical implications of this phenomenon remain unclear. 
Objectives: We examined whether cancer patients taking opioids differ in their sensitivity to a 
clinical pain stimulus using a local anesthetic injection compared to those not taking opioids. We 
also evaluated the effect of the opioid dose, duration of opioid therapy, and patients’ pain severity 
and functional status on this clinical pain stimulus. 
Study Design: Prospective observational study.
Setting: University outpatient department for interventional pain management, Republic of 
Korea.
Methods: Eighty-two cancer patients including 20 patients not taking opioids (non-opioid group) 
and 62 taking opioids (opioid group) who were scheduled for an interventional procedure were 
enrolled in this study. Patients received a standardized subcutaneous injection of lidocaine prior 
to a full dose of local anesthetic (LA). Before the injection, patients completed the Brief Pain 
Inventory (BPI) questionnaire and were asked to rate their current pain using numeric rating scales. 
Immediately following the injection, LA injection-specific pain was evaluated using pain intensity, 
unpleasantness, and behavior pain scores.
Results: LA injection-specific pain intensity, unpleasantness, and behavior pain score were 
significantly higher in the opioid group compared with the non-opioid group (P < 0.001). In the 
opioid group, these post-injection pain scores were higher in patients taking high-dose opioids 
than those taking low doses (P < 0.05). In addition, we observed a strong correlation between the 
baseline BPI pain interference score and the LA injection-specific pain score (r = 0.695, P < 0.001). 
Limitations: This study is limited by its sample size and observational design. Various opioid 
medications, which were not standardized, may have inadvertently biased our results. Finally, the 
pain assessed by a brief stimulus does not fully reflect disturbances in endogenous pain inhibitory 
processes.
Conclusion: The results of this study suggest that opioid medication is an important contributing 
factor to pain perception accompanying LA injection, and cancer patients using high-dose opioids 
may be highly susceptible to hyperalgesic responses to this clinical stimulus. We also suggest that 
the possible presence of OIH may be intensified among cancer patients with poor physical and 
psychosocial functional status. 
Key words: Adverse effects; analgesics, opioid; anesthetics, local; cancer; hyperalgesia; injections, 
subcutaneous; nociceptive pain; pain measurement; pain perception; quality of life
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cancer patients not receiving opioid treatment.We also 
evaluated the effect of opioid dose, duration of opioid 
therapy, and patients’ pain severity and functional sta-
tus on the sensitivity to this clinical pain stimulus.
Methods
This study was approved by the Institutional 
Review Board, and written informed consent was ob-
tained from all patients. Eighty-two cancer patients 
aged 20 – 70 years who were scheduled for a diagnos-
tic/therapeutic nerve block were enrolled in this study. 
Patients with any change in opioid or other analgesic 
medications less than 2 weeks prior to the scheduled 
procedure, evidence of recent disease progression by 
laboratory testing and imaging studies, and psychiatric/
central nervous system disturbance that would pre-
clude completion of the pain-related questions were 
excluded. In addition, no patients took any analgesics, 
sedatives, or opioids on the day of their procedure. 
All patients were divided into patients not taking opi-
oids (non-opioid group) and patients receiving opioid 
therapy (opioid group).
Thirty minutes before the scheduled procedure, 
all patients completed the Brief Pain Inventory (BPI) 
questionnaire (8). The BPI pain severity score includes 
4 items (worst, least, average in the last 2 weeks, and 
now) that are scored with numeric rating scales (NRSs) 
that ask the patient to rate the pain intensity on a 0 
to 10 point scale. Each scale is presented as a row of 
equidistant numbers where 0 = no pain and 10 = worst 
possible pain. Patients’ functional status was measured 
according to 7 items using the BPI pain interference 
score (7). The BPI pain interference score is measured 
with 0 representing “no interference” and 10 repre-
senting “interferes completely” with regard to how 
much pain interferes with enjoyment of life, general 
activity, walking ability, mood, sleep, normal work, and 
relations with other people. 
All interventional procedures were done as part 
of standard clinical care under either fluoroscopic- or 
ultrasound-guided techniques. The needle entry point 
was marked on the skin (all needle entry points were 
in the lumbar area), and prepared and draped in an 
aseptic manner. All patients were then informed that 
they were going to receive a little numbing medication. 
The subcutaneous LA injection was carried out by one 
pain physician (S.H.K.) using a 25-gauge needle and one 
ml 1% lidocaine to raise a small skin wheal on the previ-
ously marked needle entry point. 
Before the LA injection, patients were asked to 
Pain is the most persistent, incapacitating, and distressing symptom experienced by cancer patients (1). Opioid-based pharmacotherapy is 
the mainstay approach for the long-term treatment 
of chronic pain in populations with active cancer 
(2). However, the use of opioids in cancer patients 
is associated with the potential for detrimental 
side effects, such as constipation, drowsiness, sleep 
disturbance, cognitive impairments, opioid-induced 
hypogonadism, and tolerance (2). Moreover, many 
studies suggest that opioids may cause yet another 
problem, which is often referred to as opioid-induced 
hyperalgesia (OIH) (3). OIH is most broadly defined as 
a state of paradoxical sensitization to noxious stimuli 
caused by exposure to opioids (4). In animal studies, 
the evidence supporting OIH, which includes several 
neurobiological mechanisms, is compelling, despite 
the fact that studies are mostly limited to rodents 
(3). In humans, the evidence for OIH is mounting, but 
still controversial. Most clinical studies support the 
development of OIH in a few specific settings such 
as former opioid addicts undergoing methadone 
maintenance therapy or after acute exposure to short-
acting opioids in postsurgical patients and healthy 
volunteers using experimental pain stimuli (4,5). In these 
studies, opioid use was initiated in opioid-naive patients 
at or just before surgical incision, and the experimental 
stimuli used to assess OIH may not reflect real-life 
conditions. Other studies have sought to quantify 
OIH based on non-standardized surgical pain stimuli. 
On the contrary, a recent study using a standardized, 
clinical pain stimulus (subcutaneous administration 
of a local anesthetic [LA]) in non-cancer patients with 
chronic pain demonstrated that both the opioid dose 
and duration of treatment are directly correlated with 
pain intensity and unpleasantness in patients receiving 
opioid therapy compared with patients not receiving 
opioids (6). In clinical pain practice, cancer patients 
with chronic or acute pain are easily exposed to opioids 
and often experience interventional procedures as 
alternatives or adjuvants of opioid therapy for their 
pain control (2). Also, many cancer patients suffer 
physical and psychosocial problems such as depression 
and anxiety, catastrophizing, social impairment, and 
functional disability that can influence individual pain 
sensitivity (1,7). 
The aim of the present study was to determine 
whether cancer patients who are treated with opioids 
differ in their sensitivity to a clinical pain stimulus us-
ing a standardized subcutaneous LA injection from 
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rate their present pain score associated with their main 
pain site using a single-measure NRS (0 = no pain, 10 
= worst possible pain). Immediately after LA injection, 
injection-specific pain was evaluated using the follow-
ing 3 pain assessment methods: 
1.  Pain intensity score using a 0 to 10 NRS (0 = no pain, 
10 = worst possible pain); 
2.  Unpleasantness score using a 0 to 10 NRS (0 = no un-
pleasantness, 10 = worst possible unpleasantness); 
3.  Behavior pain score using a 0 to 10 NRS (negative 
vocalization:  0 = none,  1 = quiet moaning or 
groaning, 2 = loud moaning or groaning, crying; 
breathing: 0 = normal, 1 = labored breathing, 2 = 
noisy labored breathing, hyperventilation; facial 
expression: 0 = inexpressive, 1 = sad, frightened or 
frown, 2 = facial grimacing; body movement: 0 = 
relaxed, 1 = tense, fidgeting, 2 = rigid, pulling or 
pushing away, striking out; consolability: 0 = no 
need, 1 = distracted or reassured by voice or touch, 
2 = unable to console, distract, or reassure) (9). 
All data were recorded by an independent in-
vestigator (K.W.C.). After LA injection, patients were 
additionally given a full dose of LA to complete the 
scheduled procedure.
Clinical and demographic data were collected for 
analysis, including age, gender, procedure type, loca-
tion of pain, duration of pain, duration of opioid ther-
apy, opioid type, and opioid dose. The primary site of 
cancer and time elapsed since diagnosis were recorded. 
For patients receiving opioid therapy, regular dose was 
converted to an oral morphine equivalent dose (MED) 
according to standard accepted guidelines (10). The 
daily MED was reconverted to none, low (one to 59 mg), 
intermediate (60 to 199 mg), and high (≥ 200 mg) opi-
oid doses for our study population. A lot of controversy 
and variation exist in determining opioid dose ranges, 
especially in high-dose ranges. However, a daily MED 
more than 200 mg seems to be considered a high dose 
of opioids in clinical practice (2). For sub-analysis in the 
opioid group, patients were divided into those with an 
NRS injection-specific pain score more than 7, which is 
typically thought to indicate severe pain (hyperalgesic 
group), and those with an NRS pain score less than 7 
(non-hyperalgesic group).
Statistical Analysis
Sample-size calculation was performed based on 
a previous study in non-cancer patients (6) with the 
following assumptions: 80% power to detect a 1.5 
difference in the LA injection pain score between the 
non-opioid group and the opioid group with a stan-
dard deviation of 2.8 and an alpha level of 0.05 with 
an independent t-test using the power analysis and 
sample size package (NCSS, LLC, Kaysville, UT). We cal-
culated that 55 patients would be required. Continu-
ous data are reported as mean and standard deviation 
unless otherwise indicated. Normality of data distribu-
tion was assessed using the Kolmogorov–Smirnov test. 
Categorical data are reported as both the number of 
patients and percentage. Statistical analyses were per-
formed with the SAS (version 9.2; SAS Institute, Inc., 
Cary, NC). Demographic data were analyzed with an in-
dependent t-test, chi-square test, or Fisher’s exact test, 
as appropriate. By designating one variant as a factor 
and the other variants as dependents, one-way analy-
sis of variance was used to detect overall differences 
between means. When significant main effects were 
observed, post-hoc Tukey Honestly Significant Differ-
ence testing was performed to determine the source(s) 
of the differences. This analysis was repeated for each 
factor analyzed (e.g., age, gender, opioid dose, opioid 
treatment duration). The Pearson correlation analysis 
was used to test the associations between pre-injection 
and post-injection pain scores. To identify independent 
predictors for a hyperalgesic response to LA injection 
stimulus, multivariate logistic regression analysis (Exact 
logistic regression model) was used and adjusted odds 
ratio (OR) with 95% confidence interval (CI) was cal-
culated. A P value < 0.05 was considered statistically 
significant.
Results
Demographic Data 
Eighty-two cancer patients were enrolled in this 
study. Patients consisted of 20 patients not taking opi-
oids (non-opioid group) and 62 patients taking opioids 
(opioid group). Patient characteristics, pain duration, 
and cancer-related data for the 2 groups are shown in 
Table 1. There were no significant differences in gen-
der, age, weight, pain duration, primary sites of cancer, 
and time elapsed since cancer diagnosis between the 2 
groups. Lower back (n = 62), buttocks (n = 19), legs (n 
= 12), and abdominal region (n = 4) were noted as the 
main pain sites. Patients enrolled in this study under-
went a variety of interventional procedures including 
interlaminar epidural block (n = 13), selective transfo-
raminal epidural block (n = 21), medial branch block (n 
= 28), sympathetic block (n = 7), trigger point injection 
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(n = 9), and others (n = 4). Table 2 shows daily opioid 
dose (MED), duration of opioids, and opioid medication 
type in the opioid group. Thirty-one percent of patients 
were taking more than one type of opioid. There were 
no differences in average daily MED, duration of opi-
oids, or duration of pain between male and female 
patients. 
Pain Scores Before and After LA Injection 
Stimulus
Table 3 shows the overall pain assessment scores 
before and after standardized LA injection between 
the non-opioid group and the opioid group. The mean 
baseline BPI scores and pre-injection pain score (pain 
score associated with the patient’s main pain site) were 
higher in the opioid group than in the non-opioid 
group. The mean injection-specific pain intensity, 
unpleasantness, and behavior pain scores were signifi-
cantly higher in the opioid group compared with the 
non-opioid group. These differences were independent 
of the pain duration, cancer duration, and gender (P > 
0.05). There were no differences in post-injection pain, 
unpleasantness, and behavior pain scores between men 
and women (P = 0.132, P = 0.413, and P = 0.337, respec-
tively). In addition, the injection-specific pain intensity 
score was correlated with the baseline BPI pain severity 
score (r = 0.315, P = 0.005), pre-injection pain score (r = 
0.401, P < 0.001), and most strongly with the BPI pain 
interference score (r = 0.695, P < 0.001; Fig. 1).
Pain Scores Based on Opioid Dose and 
Duration of Opioid Use After LA Injection 
Stimulus
Opioid use was categorized by dose, and post-
injection pain intensity, unpleasantness, and behavior 
pain score based on the daily opioid dose are shown 
in Fig. 2. Post-injection pain intensity, unpleasantness, 
and behavior pain scores were significantly higher in 
patients receiving a daily MED of more than 200 mg 
(high dose) compared with patients receiving a low 
dose of opioids (P = 0.017, P = 0.021, P = 0.012, respec-
tively). Unpleasantness scores were significantly higher 
in patients receiving high dose opioids than those re-
ceiving intermediate doses (P = 0.019). Opioid use was 
next categorized by duration, and post-injection pain 
intensity, unpleasantness, and behavior pain scores 
based on opioid duration are shown in Fig. 3. There 
were no differences in overall post-injection pain scores 
between patients taking opioids < one year and ≥ one 
year (P = 0.799, P = 0.673, P = 0.910, respectively). In the 
opioid group, there were no significant differences in 
baseline BPI and pre-injection pain score in the catego-
ries of opioid dose and duration of opioid use, except 
for the BPI interference pain score, which was higher in 
patients taking a high opioid dose than those taking a 
low dose (P = 0.01). 
Table 1. Demographic characteristics
Non-opioid  
group (n=20)
Opioid group  
(n=62)
Gender (M/F), n 9/11 35/27
Age, years 62.8±12.7  (52-85) 62.4±9.9  (45-82)
Weight, kg 62.3±10.4  (54-84) 57.7±9.8 (42-81)
Pain duration, 
months
24.0±24.5 
(3 months-8 years)
18.0±23.0 
(3 months-9 years)
Time elapsed since 
cancer diagnosis, 
months
31.6±34.8
(3 months-10 years)
39.4±29.5
(6 months-10 years)
Primary sites of  cancer, n
  Lung 5 14
  Breast 5 10
  Liver 3 9
  Colon 4 11
  Prostate 3 9
  Other sites 1 9
Values are means ± SD (range) or number of patients. No significant 
differences were noted between the 2 groups. 
Table 2. Opioid medications data in the opioid group (n=62).
Duration of  opioid use, mo. 14.0±13.7 (1 month-6 years)
  < 1 year, n 35
  ≥1 year, n 27
Daily opioid dose, mg 188.4±229.8 (10-1080)
  Low (1 to 59 mg) , n 25
  Intermediate (60 to 199 mg), n 21
   High (≥200 mg), n 16
Type of  opioid, n Median dose (range)
   Oxycodone (n=38) 30 mg/day (2.5-280)
   Morphine (n=6) 90 mg/day (15-400)
   Hydromorphone (n=8) 12 mg/day (4-64)
   Codeine (n=9) 50 mg/day (30-100)
   Transdermal fentanyl (n=17) 25 mcg/h (12.5-150)
Values are means ± SD (range), median (range) or number of patients. 
Doses are given in daily oral morphine equivalents.
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Hyperalgesic vs. Non-hyperalgesic Patients 
in Response to LA Injection Stimulus Among 
Patients Taking Opioids
The results of comparison between hyperalgesic 
and non-hyperalgesic patients in response to the LA 
injection stimulus in the opioid group are shown in 
Table 4. Patient characteristics and pain duration were 
similar between the 2 groups. The mean daily opioid 
dose was significantly higher in hyperalgesic patients 
than in non-hyperalgesic patients (P = 0.004). There 
were no differences in baseline BPI pain severity and 
Table 3. Pain assessment scores before and after LA injection stimulus.
Non-opioid group 
(n=20)
Opioid group 
(n=62)
P value
Baseline pain scores (0 to 10 NRS)
BPI pain severity score (4 items) 23.9±5.2 29.7±7.4 < 0.001
BPI pain interference score (7 items) 32.9±12.5 46.1±12.0 < 0.001
Pre-injection pain score* 5.7±1.2 6.7±1.6 0.007
Injection-specific pain scores (0 to 10 NRS)
Pain intensity score 3.3±1.6 6.1±1.5 < 0.001
Unpleasantness score 1.9±1.6 4.7±1.9 < 0.001
Behavior pain score 2.0±1.7 5.3±1.8 < 0.001
Values are means ± SD. LA, local anesthetic; BPI, Brief Pain Inventory; NRS, numeric rating scale. * Pre-injection pain score means pain score 
associated with patient’s main pain site. 
Fig. 1. Relationship between the baseline BPI pain interference score and the LA injection-specific pain score (r = 0.695, P < 
0.001).
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Fig. 2. Standardized LA injection-specific pain 
(A), unpleasantness (B), and behavior pain 
score (C) as a function of  the opioid dose. Dos-
es are given in daily oral morphine equivalents: 
1= no opioids; 2=1 to 59 mg (low); 3 = 60 to 
199mg (intermediate);  4= ≥200mg (high). 
Error bars show 95 % confidence intervals. * 
P < 0.01 compared with group 1 (non-opioid 
group). †P < 0.05 for group 2 (low dose) vs. 
group 4 (high dose). ‡ P < 0.05 for group 3 
(intermediate dose) vs. group 4 (high dose).
Fig. 3. Standardized LA injection-specific pain 
(A), unpleasantness (B), and behavior pain 
score (C) as a function of  opioid use duration. 
1 = no opioids; 2 = ≤1 year; 3  =≥1 year. Error 
bars show 95 % confidence intervals. * P < 0.01 
compared with group 1 (non-opioid group).
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pre-injection pain scores between the 2 groups, but the 
BPI pain interference score was significantly higher in 
hyperalgesic patients compared with non-hyperalgesic 
patients (P = 0.001). Multivariate regression analysis 
showed that high opioid dose (reference-low dose, 
OR 11.01, 95% CI: 1.42 - 41.02, P = 0.024) and the BPI 
pain interference score (per 10 points, OR 3.27, 95% 
CI: 1.10 - 9.84, P = 0.033) remained independent risk 
factors for a hyperalgesic response to LA injection pain 
after controlling for age, gender, pain duration, pre-
injection pain scores, duration of opioid use, and daily 
opioid dose.
discussion
In this study, we demonstrated that pain intensity, 
unpleasantness, and behavior pain scores in response 
to an LA injection stimulus were significantly higher 
in cancer patients receiving opioid therapy compared 
with cancer patients not taking opioids. We also 
found that high-dose opioid administration and poor 
functional status intensified this clinical pain in cancer 
patients receiving opioid therapy.
We sought to assess OIH based on the same 
clinical model previously described by Cohen et al 
(6). However, our study design has several differences 
and attempts to complement some shortcomings of 
their study. First, our study was conducted in a cancer 
patient subgroup. In our country, opioid prescriptions 
in non-cancer patients are relatively rare (11). Second, 
LA injections were only performed in the lumbar re-
gion in our study. The perception of LA injection pain 
showed different responses in different injection sites 
in their study. Third, in addition to patient-reported 
pain scores, we used observer-assessed pain scores to 
evaluate injection-specific pain intensity. Finally, we in-
dependently considered the patients’ functional status 
including several physical and psychosocial factors.  
We used 3 methods to assess LA injection-specific 
pain sensitivity because different tests for pain sen-
sitivity do not necessarily lead to the same results. 
For instance, unpleasantness may be a more reliable 
indicator of pain tolerance, whereas pain score bet-
ter reflects the nociceptive threshold (6). Pain-related 
behavior may represent involuntary responses to acute 
pain, although the behavioral pain score was originally 
developed in unconscious patients, dementia patients, 
and children (12). Our results showed that patient-
reported pain intensity, unpleasantness scores, and 
observer-assessed behavior pain scores in response to 
LA injection pain were significantly higher in patients 
Table 4. Comparison between non-hyperalgesic (<7 NRS) and hyperalgesic (≥7 NRS) patients in response to LA injection stimu-
lus in the opioid group.
Non-hyperalgesia 
(n=39)
Hyperalgesia (n=23) P value
Duration of opioid use, months 10.1±11.0(1 month-3 years)
16.4±17.4
(1 month-6 years) 0.155
    <1 year, n 24 11
    ≥1 year, n 15 12
Daily opioid dose, mg 101.3±77.0(10-300)
298.5±304.6
(20-1080) 0.004
    Low (1 to 59 mg) , n 22 3
    Intermediate (60 to 199 mg) , n 14 7
    High (≥200 mg), n 3 13
Baseline pain scores (0 to 10 NRS)
    BPI pain severity score (4 items) 29.8±9.3(18-36)
29.6±4.3
(20-36) 0.905
    BPI pain interference score (7 items) 40.9±12.4(16-59)
52.4±8.2
(32-64) 0.001
    Pre-injection pain score* 6.4±1.6(3-9)
7.2±1.4
(4-10) 0.109
Values are means ± SD (range) or number of patients. Doses are given in daily oral morphine equivalents. LA, local anesthetic; BPI, Brief Pain 
Inventory; NRS, numeric rating scale. * Pre-injection pain score means pain score associated with patient’s main pain site.
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receiving opioid therapy compared with those not 
taking opioids. We also observed that all pain assess-
ment scores in response to LA injection pain were 
significantly higher in patients receiving a high dose 
of opioids compared with those receiving a low dose. 
Although the overall effect of a given opioid dose is 
the composite response resulting from activation of 
opioid-dependent pronociceptive and antinociceptive 
systems according to human and animal studies (3), OIH 
has been more commonly reported in patients receiv-
ing high doses of opioids rather than low or moderate 
doses (3,4). The majority of the previous human data 
regarding high dose OIH are associated with very high, 
clinically unusual doses of opioids via systemic or intra-
thecal administration, but our observation shows that 
patients taking higher doses of opioids that are com-
monly used in an outpatient setting tend to perceive 
more pain to a clinical stimulus. On the contrary, the 
relationship between the duration of opioid treatment 
and the perception of pain accompanying an LA injec-
tion was unclear in our study. A previous study in which 
long-acting oral morphine was given to chronic back 
pain patients demonstrated measurable hyperalgesia 
within one month of beginning therapy (13). Also, a 
recent study with a mouse model of post-surgical pain 
showed that remifentanil induces a pronociceptive 
effect that is dose dependent but not altered by the 
duration of administration (14). Apart from opioid 
dose and duration of opioid use, opioid type accord-
ing to structural difference and distinctions between 
long- and short-acting opioids due to subliminal with-
drawal may affect pain sensitivity (3,15). We could not 
standardize this potential confounding factor because 
selection of the opioid was influenced by our referring 
doctor’s judgment, preconceptions concerning opioid 
therapy, and limited types of opioids predominantly 
used in our institution. However, baseline pain scores 
were not statistically different among patients using 
opioids in our analysis. 
On the other hand, there was no gender difference 
in post-injection pain scores regardless of opioid dose 
in our study. In cancer patients, few research studies on 
gender differences in pain have been published and 
are restricted to studies of the differences in severity 
scores; they have mostly yielded inconsistent results 
(16). Collectively, our study suggests that opioid medi-
cation itself, regardless of opioid treatment duration, 
is an important contributing factor to pain perception 
accompanying LA injection, and patients using high 
doses of opioids are highly susceptible to hyperalgesic 
responses to this clinical stimulus. This result is generally 
consistent with previous studies involving methadone 
maintenance patients (17), surgical patients (18), and 
patients with non-cancer chronic pain, all of which 
support the OIH phenomenon (6). However, although 
our study design was straightforward, we focused on 
exploring evidence for OIH in a real medical setting. 
Namely, various opioid medications and interventional 
procedures are important treatment modalities for 
pain in cancer patients, and LA injection pain as the 
nociceptive stimulus is more realistic than experimental 
stimulation.
The BPI is a well-known multidimensional pain 
questionnaire that provides information about pain 
severity and the degree to which the pain interferes 
with physical and social functioning, mood, sleep, and 
enjoyment of life (8). An interesting observation in our 
study was the strong negative correlation between 
post-injection pain scores and functional status, which 
is represented as the BPI pain interference score. Cancer 
patients with poor functional status tended to show a 
more painful response to an LA injection stimulus in our 
study. Although pain level in cancer patients has been 
shown to have a negative association with their func-
tional status (7), definitive information regarding an as-
sociation between the OIH phenomenon and patients’ 
functional status or psychosocial conditions is currently 
lacking. However, a previous study in patients undergo-
ing methadone maintenance treatment showed that 
chronic severe pain is closely linked to low physical and 
social functioning and psychiatric distress (19). Recent 
studies also demonstrated the important role of psy-
chopathologic and psychosocial conditions as predictors 
of failed opioid effectiveness (20), and hyperalgesia to 
pressure pain is associated with decreased quality of life 
in non-cancer chronic pain subgroups (21). 
Among the neurobiological mechanisms proposed 
to explain OIH, the central glutaminergic system is 
the most common possibility (4,5). The excitatory 
neurotransmitter N-methyl-d-aspartate (NMDA) plays 
a central role in the development of OIH because ad-
ministration of the NMDA receptor antagonist MK-801 
or ketamine reverses the development of OIH (22,23). 
Similarly, pathologic activation of NMDA receptors is 
closely related to various aspects of emotionality in-
cluding fear, anxiety, and depression, as well as impair-
ment of cognitive function (24). Consequently, these 
current data suggest that the OIH phenomenon and 
worsening of psychosocial function, even though dis-
tinct processes, may share common cellular mechanisms 
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